摘要
目的:探讨葛根素联合常规抗骨质疏松治疗对老年行人工髋关节置换术后骨密度的影响。方法:选取2015年5月至2016年5月重庆市开州区人民医院收治的行人工髋关节置换术治疗的老年女性患者58例,采用随机数字表法分为观察组和对照组,每组29例,2组均行人工髋关节置换术治疗,术后14 d对照组给予口服钙尔奇D片+骨化三醇胶丸+静脉点注唑来膦酸,观察组同时静脉点注葛根素注射液,2组均连续治疗2个月,术后于门诊随访6个月。统计2组临床治疗效果及不良反应发生情况,术后采用Harris评分系统评估2组髋关节功能,并检测假体周围骨密度。结果:治疗后观察组有效率86. 21%,对照组有效率79. 31%,2组比较差异无统计学意义(P> 0. 05)。从术后7 d至术后6个月2组Harris评分及髋关节功能优良率呈现逐渐升高的趋势,且术后3个月及术后6个月观察组均高于对照组(P <0. 05或P <0. 01)。与术后3个月比较,术后6个月观察组假体各分区骨密度无明显变化,对照组R4~R7区骨密度降低,且术后6个月观察组R6、R7区骨密度明显高于对照组(P <0. 05或P <0. 01)。治疗期间,2组均有不同程度的发热、肌痛、流感样症状、骨关节疼痛及头痛,2组不良反应发生率差异无统计学意义(P> 0. 05)。结论:老年骨质疏松女性患者行人工髋关节置换术后应用葛根素联合常规抗骨质疏松治疗,临床疗效显著,患者的髋关节功能及假体周围骨密度均得到有效提升,且安全性好。
Objective:To investigate the effects of puerarin combined with conventional anti-osteoporosis therapy on bone density after artificial hip arthroplasty in elderly patients.Methods:A total of 58 elderly women who were treated with artificial hip arthroplasty in The People′s of Hospital Kaizhou District from May 2015 to May 2016 were selected and divided into experiment group(n=29)and control group(n=29)according to computer generated random digital table.The 2 groups were treated with artificial hip arthroplasty.14 days after the treatment,the control group was given oral calcium Erqi D tablets,ossification triol capsules and intravenous infusion of zoledronic acid,and the experiment group was given intravenous infusion of puerarin injection based on the control group.The 2 groups were treated continuously for 2 months,and the patients were followed up for 6 months.The clinical therapeutic effects and incidence of adverse reactions were collected,and the hip function was assessed by Harris scoring system and the bone density around the prosthesis was measured.Results:The effective rate was 86.21%in the experiment group and 79.31%in the control group,it had no statically difference between the 2 groups(P>0.05).The Harris score and hip function was gradually increasing from 7 days to 6 months after operation,and the experiment group were higher than the control group 3 and 6 months after surgery(P<0.05 or P<0.01).Compared with 3 months after operation,there was no significant changes in bone density in the experiment group at 6 months after operation,R4-R7 of the bone density in the control group decreased,R6 and R7 of the bone density in the experiment group was significantly higher than those in the control group at 6 months after operation(P<0.05 or P<0.01).During the treatment,the 2 groups had varying degrees of fever,myalgia,flu-like symptoms,joint pain and headache,and the incidence of adverse reactions in the 2 groups had no significant difference(P>0.05).Conclusion:The clinical efficacy of puerarin combined with conventional anti-osteoporosis treatment after artificial hip arthroplasty therapy in elderly female patients with senile osteoporosis is significant,and the hip function and the bone density around the prosthesis are effectively improved and the safety is good.
作者
贺燕
周吉银
李光灿
李秀池
He Yan;Zhou Jiyin;Li Guangcan;Li Xiuchi(Pharmacy Department,The People′s of Hospital Kaizhou District,Chongqing 405400,China;National Drug Clinical Trial Institution,Army Medical University,Chongqing 400037,China)
出处
《世界中医药》
CAS
2019年第2期399-402,共4页
World Chinese Medicine
基金
国家自然科学基金面上项目(81770806)
重庆市基础与前沿研究计划重点项目(cstc2015jcyjBX0138)